

Markers of endothelial activation and damage in haematological patients in relation to efficacy of transfusion support: a pilot study

Submission date 07/03/2007	Recruitment status No longer recruiting	☒ Prospectively registered
Registration date 07/03/2007	Overall study status Completed	☐ Protocol
Last Edited 02/09/2008	Condition category Haematological Disorders	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr J L H Kerkhoffs

Contact details

Haga Hospital
Leyweg 275
Den Haag
Netherlands
2545 CH
+31 (0)70 359 2004
J.Kerkhoffs@hagaziekenhuis.nl

Additional identifiers

Protocol serial number

NTR909

Study information

Scientific Title

Acronym

The marker study

Study objectives

Efficacy of transfusion support depends on disease and treatment related patient factors. Markers of endothelial damage have been identified, but until today not in relation to the efficacy of transfusions.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Non-randomised, parallel group clinical trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Sickle cell disease

Interventions

Patients with a haemato-oncological diagnosis will receive platelet transfusion and patients with sickle cell disease will receive red blood cell exchange. Two blood samples will be drawn, before and after this intervention, and these samples will be used to test several known markers of endothelial cell activation/damage.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Efficacy of platelet transfusion or red blood cell exchange transfusion in haemato-oncological patients and sickle cell patients, respectively, in relation to several endothelial activation markers.

Key secondary outcome(s)

No secondary outcome measures

Completion date

01/04/2008

Eligibility

Key inclusion criteria

1. Age greater than 18 years
2. Haemato-oncological disease
3. Sickle cell disease
4. Informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

Not Specified

Key exclusion criteria

1. Active cardiovascular disease
2. Recent thrombo-embolism

Date of first enrolment

01/04/2007

Date of final enrolment

01/04/2008

Locations**Countries of recruitment**

Netherlands

Study participating centre

Haga Hospital

Den Haag

Netherlands

2545 CH

Sponsor information

Organisation

Sanquin Blood Bank South West Region (The Netherlands)

ROR

<https://ror.org/01fm2fv39>

Funder(s)**Funder type**

Hospital/treatment centre

Funder Name

Sanquin Blood Bank South West Region (The Netherlands)

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration